【布汝斯-艾爾沃德 WHO 談武漢新冠病毒】

 

 

"There is only one drug right now that we think may have real efficacy and that's Remdesivir," 

Bruce Aylward, an assistant director-general of the World Health Organization (WHO), said at a press conference in Beijing.
布汝斯-艾爾沃德 醫學博士

加拿大流行病學家 同時供職世衛組織
WHO officials said clinical trials for Remdesivir in humans are now taking place and results should be available within weeks.

 

艾爾沃德 醫生的這句話，很重要，

如何精確地翻譯和領悟需要點兒思考。

 

原文，直譯是：

目前隻有一個藥，我們認為，也許有真效，

即 瑞木岱西維爾。

 

1，鼓噪 雙黃連液 抗新冠病毒 純屬欺詐和商業犯罪，必須追查！

 

2，曹彬教授的武漢瑞藥試驗堪虞堪憂，還有一個多月，能否如期如願完成，存疑。另，試驗已經三周，有何端倪眉目，應有所顯露了！

 

3，應知醫學藥學試驗的設計和基本要素，條件的嚴苛性，不能缺少基本的條件和時間過程。

 

4，布汝斯說瑞藥是可能唯一真有效藥物，是實話實說，關鍵是限定詞 may 也許。換言之，也許沒效。他的話其實是對目前吹噓的其它藥物和亂七八糟的試驗的否定，棒殺的對！我支持。（氯喹等就是瞎哄哄的例子之一，當然也許真有效果的還在路上，路漫漫其修遠兮，吾將上下而求索 。科研醫學臨床要看實效，不是也不能一蹴而就，得來全不費工夫！）

 

5，瑞藥對Ebola伊波拉病毒基本無效，而非本文吹的很有效！這是我對此文持批判的根本！

 

6，國內現在是病急亂投醫亂用藥，部分心情可以理解。所以200多試驗項目中有20個可以理解和允許，畢竟八仙過海，不能一棵歪脖樹上吊死。

 

7，李蘭娟教授說有兩三種藥，體外試驗有抗新冠病毒作用，看後啞然失笑！1，體外效果和人體內差108000裏，2，科學試驗沒這麽無雲就放炮打雷的。等有臨床效果再宣稱什麽，來得及， 慌什麽？3，我有更好的藥物，100%見效，硫酸！強酸，火堿，能用嗎？！笑話！

 

Dr. Bruce Aylward, 

former Assistant Director-General of the WHO and 

senior advisor to WHO Director-General.

 

 

Dr Bruce Aylward received his MD at Memorial University, St. John’s, Newfoundland, in Canada in 1985.

So first, what has China done?

 

艾爾沃德，明人快語，直切主題的演講

 

In the face of a previously unknown disease, China has taken one of the most ancient approaches for infectious disease control and rolled out probably the most ambitious, and I would say, agile and aggressive disease containment effort in history. China took old-fashioned measures, like the national approach to hand-washing, the mask-wearing, the social distancing, the universal temperature monitoring. 

 

艾爾沃德 對中國的戰疫舉措感悟至深，

他稱之為 

中國采用了最古老的，

最大手筆的戰疫措施，

超乎了人們的想象力。

 

But then very quickly, as it started to evolve, the response started to change. And it moved from this sort of one-size-fits-all approach to a science-and-risk-based approach, which was really tailored to allow it to use different containment approaches and measures,depending on the context, the capacity and really the nature of the coronavirus circulation. 

 

So they refined the strategy as they moved forward, and this is an important aspect as we look to how we might use this going forward.A couple of things have differentiated. The first, they took this old approach and then turbo-charged it with modern science and modern technology in a way that was unimaginable even a few years ago. Just a couple of small examples. 

 

As they cleared these giant hospitals to make space for overwhelming numbers of COVID-19 cases, they moved a huge amount of the routine provision of medical services onto online platforms and other mechanisms that they’ve really come to a cutting edge with. And when we were in Sichuan, wondering how they were working with the remote areas, they showed us that they have prioritized a roll out of a 5G platform so that they could do real-time contact, support, with investigators in the field, we asked to see it, and in two minutes up on the big screen they pull up an epidemiological investigation team that was in the field, was having problems with something hundreds of kilometers away, and was getting walked through it by the top experts from the province. 

 

So it brought a lot of attention to understand this strategy, because it’s fundamentally different to the way most people think about approaching a dangerous respiratory pathogen in the modern era.And this brought us to the second issue about how did they make it happen, make the strategy actually translated in impact? 

 

What they’ve done has only been possible because of tremendous collective commitment and will of the Chinese people from the most bottom-level community leaders we met and talked to, to the governors at the top. It was an extraordinary, what we call all-of-government, all-of-society approach that many of you are feeling because you live here and you operate it. But it is rare to see that.

There was one aspect of this that struck us as particularly important. You’ve been hearing about the challenges we are having with the global supply chain and PPE, and many countries start piling and hoarding this. But what we found out was, even though every province was suffering outbreaks, was getting infected, the governors were prioritizing the movement of medical teams and PPE out to Hubei and Wuhan. That’s a very important method for the rest of the world about how we work in the kind of solidarity and collaborative action that’s going to be needed to beat this virus.So first, understanding the strategy was key, then how it was applied and got to the incredible level of application. 

 

But the key thing is, of course, has it made a difference? 

Has China made an impact on this virus? That’s the next question.And it’s the opinion of the joint mission, after looking at it very closely and in different ways, that there is no question that China’s bold approach to the rapid spread of  this new respiratory pathogen has changed the course of what was a rapidly-escalating and continues to be deadly epidemic.I think one of the most compelling statistics is, when I arrived here on the first day, just over two weeks ago, I don’t remember the day now, I think it’s 9thor 10thof February, anyway, there were 2,478 new cases of COVID-19 being reported every single day, 2,500 new cases being reported every single day when I arrived. 

 

布汝斯-艾爾沃德 

在北京 WHO-China 有關武漢新冠病毒發布會上

講話全文：（WHO提供）

 

 【 艾爾沃德談新冠病毒全文】?

 

 

世衛組織薩斯-2 考察團來到中國北京，

先去了四川，廣東，然後到武漢，

又回到北京。

 

前幾天 有幾隻菜鳥嘰嘰喳喳，

說我國掩蓋災情，不讓考察團去湖北武漢，

事實打了這幫小醜一記漂亮的耳光！

 

另外幾隻 喳喳唧唧，

說美國病毒專家來中國是為了竊取標本，

其實，這次世衛組織考察團12名成員中

當然有美國專家參與。

 

害怕論，遮掩論，陰謀論，盜竊犯 的

這些謠言又被擊的粉碎！

 

奉勸那些豬鼻子插蔥充象的貨，

以後少裝大尾巴狼！

 

Merdad Parsey, MD, PhD 

Gilead’s Chief Medical Officer, 

美國吉利德藥廠 首席醫務官 帕希

 

He completed his MD and PhD at the 

University of Maryland, Baltimore, 

               his residency in Internal Medicine at 

Stanford University and his fellowship in Pulmonary and                        Critical Care Medicine at the 

University of Colorado.

 

He was Assistant Professor of 

Medicine and Director of Critical Care Medicine at the 

New York University School of Medicine.